Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial

HIV Clinical Trials, 05/25/2012

Compared with the standard RBV dose (800 mg/day), weight–based RBV dosing (1000/1200 mg/day) did not significantly increase SVR rates, but did increase the incidence of anemia in HIV–HCV (genotype 1) coinfected patients.

Print Article Summary Cat 2 CME Report